RadNet (NASDAQ:RDNT) Stock Price Expected to Rise, Truist Financial Analyst Says

Key Points

• Truist Financial raised RadNet’s price target from $90 to $94 and maintained a “buy” rating, implying approximately 24% upside from the prior close. Analysts overall have a “Moderate Buy” consensus with an average target of $88.
• RadNet reported quarterly revenue of $622.7 million, up 25% year over year and above estimates, while EPS of $0.29 exceeded expectations. Strong imaging demand and rapid Digital Health growth led management to raise its 2026 revenue, adjusted EBITDA and free-cash-flow guidance.
• Risks remain: adjusted EPS and GAAP net income declined year over year, Digital Health EBITDA fell as investment increased, and recent insider activity consisted of stock sales with no purchases.

RadNet (NASDAQ:RDNT - Get Free Report) had its price target raised by stock analysts at Truist Financial from $90.00 to $94.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the medical research company's stock. Truist Financial's target price points to a potential upside of 23.95% from the stock's previous close.

Several other research firms have also commented on RDNT. Jefferies Financial Group restated a "buy" rating on shares of RadNet in a research note on Friday, July 31st. Weiss Ratings restated a "sell (d-)" rating on shares of RadNet in a research report on Friday. Zacks Research downgraded RadNet from a "hold" rating to a "strong sell" rating in a research note on Monday, July 13th. Finally, Barclays lowered their price objective on RadNet from $70.00 to $65.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 20th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, RadNet has a consensus rating of "Moderate Buy" and an average price target of $88.00.

RadNet Stock Performance

RDNT stock traded down $1.44 during trading on Tuesday, reaching $75.84. The stock had a trading volume of 293,318 shares, compared to its average volume of 837,861. The firm has a market cap of $5.96 billion, a PE ratio of -420.69 and a beta of 1.36. The company has a current ratio of 1.17, a quick ratio of 1.17 and a debt-to-equity ratio of 0.79. The stock's 50 day moving average is $61.44 and its two-hundred day moving average is $61.71. RadNet has a 52 week low of $50.82 and a 52 week high of $85.84.

RadNet (NASDAQ:RDNT - Get Free Report) last released its quarterly earnings results on Sunday, August 9th. The medical research company reported $0.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.19 by $0.10. RadNet had a positive return on equity of 2.77% and a negative net margin of 0.66%.The business had revenue of $622.72 million during the quarter, compared to the consensus estimate of $610.87 million. During the same period in the previous year, the company posted $0.31 EPS. The business's quarterly revenue was up 25.0% compared to the same quarter last year. As a group, equities analysts anticipate that RadNet will post 0.52 earnings per share for the current year.

Insider Activity at RadNet

In related news, CEO Cornelis Wesdorp sold 4,750 shares of the company's stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $58.11, for a total transaction of $276,022.50. Following the sale, the chief executive officer owned 69,075 shares of the company's stock, valued at $4,013,948.25. This represents a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David L. Swartz sold 2,699 shares of the stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $53.89, for a total transaction of $145,449.11. Following the transaction, the director owned 177,013 shares of the company's stock, valued at $9,539,230.57. This trade represents a 1.50% decrease in their position. The SEC filing for this sale provides additional information. 5.14% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in RDNT. Geneos Wealth Management Inc. bought a new stake in RadNet during the fourth quarter worth approximately $25,000. Allworth Financial LP lifted its stake in shares of RadNet by 346.6% in the 3rd quarter. Allworth Financial LP now owns 393 shares of the medical research company's stock valued at $30,000 after purchasing an additional 305 shares during the last quarter. Danske Bank A S bought a new stake in shares of RadNet in the 3rd quarter valued at approximately $30,000. Eurizon Capital SGR S.p.A. purchased a new position in shares of RadNet in the 4th quarter worth approximately $36,000. Finally, Harbour Investments Inc. bought a new position in shares of RadNet during the 4th quarter valued at approximately $42,000. Institutional investors own 77.90% of the company's stock.

Key Headlines Impacting RadNet

Here are the key news stories impacting RadNet this week:

• Positive Sentiment: Record revenue and EBITDA: Q2 revenue rose 25% year over year to $622.7 million, exceeding the $610.9 million consensus estimate, while adjusted EBITDA increased 22.7% to a record $99.7 million. RadNet Q2 financial results
• Positive Sentiment: Imaging demand remained strong: Aggregate MRI, CT and PET/CT procedures increased 21.2%, while same-center advanced-imaging volume grew 9.6%. The mix of higher-value procedures improved the Imaging Center segment’s adjusted EBITDA margin to 16.1%.
• Positive Sentiment: Guidance was raised: RadNet increased its 2026 Imaging Center revenue guidance to $2.37 billion-$2.42 billion, adjusted EBITDA guidance to $345 million-$358 million and free-cash-flow guidance to $115 million-$125 million. RadNet healthcare update
• Positive Sentiment: Digital Health is expanding rapidly: Segment revenue climbed 56.5% to $32.4 million, and annual recurring revenue nearly doubled to $105.5 million. A newly FDA-cleared breast-ultrasound AI product and additional health-system partnerships could support future growth.
• Neutral Sentiment: Management’s earnings call highlighted acquisitions, joint ventures and investments in DeepHealth AI and enterprise imaging as long-term growth drivers, but investors are weighing the time required for these initiatives to generate returns. RadNet Q2 earnings call transcript
• Negative Sentiment: Profitability weakened: Adjusted EPS fell to $0.29 from $0.34 a year earlier, although it beat estimates of $0.19. GAAP net income attributable to shareholders also declined to $7.5 million from $14.5 million.
• Negative Sentiment: Digital Health adjusted EBITDA dropped 27.2% to $2.5 million as RadNet increased spending on personnel, infrastructure, sales and research and development. The company also posted a $25.9 million first-half net loss, compared with a $23.5 million loss last year.
• Negative Sentiment: Reported insider activity showed nine open-market sales and no purchases over the past six months, which may add pressure to sentiment at an elevated valuation. RadNet record Q2 results

About RadNet

RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.

Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source